Larry Cai

CBO at Defand Therapeutics

Presenter

Defand Therapeutics revolutionizes the discovery and development of target protein degradation assets, deploying DEFUSE, its target-centric, patented high throughput screening platform that shifts the discovery paradigm of molecular glue degraders, making rational design of small molecule degraders of high value disease targets a reality.